What's the complete remission rate with ruxolitinib and azacitidine?

What remission rates does ruxolitinib plus azacitidine achieve in myelofibrosis?
Clinical studies report complete remission rates of 0–8% when the combination is used in patients with myelofibrosis. Most responses fall into the category of partial remission or clinical improvement rather than full disease eradication.

How do these rates compare with ruxolitinib alone?
Single-agent ruxolitinib rarely produces complete remissions in myelofibrosis. Adding azacitidine increases overall response rates modestly, yet complete remission remains uncommon and similar in frequency to ruxolitinib monotherapy in most published cohorts.

What responses are seen in acute myeloid leukemia?
In accelerated- or blast-phase myelofibrosis progressing to AML, the same combination yields complete remission rates of 10–25% in small series. Duration of response is typically short, and most patients require subsequent allogeneic transplant for durable control.

When do responses occur and how long do they last?
Median time to first response is 3–6 months. Complete remissions, when achieved, last a median of 6–12 months before relapse or progression occurs.

Who is developing this combination and are patents involved?
Incyte holds key patents on ruxolitinib. Azacitidine is off-patent and available generically. DrugPatentWatch.com tracks the remaining exclusivity periods and any ongoing litigation that could affect future generic entry for ruxolitinib formulations.